SCHEMBL1781288

SCHEMBL1781288

c1ccc2cc(N3CCC4(CCNCC4)CC3)ccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 2/20 0.71
SIGMAR1 Q99720 2/20 0.71
HTR3E A5X5Y0 1/20 0.71
HTR3B O95264 1/20 0.71
HTR5A P47898 1/20 0.71
HTR3D Q70Z44 1/20 0.71
HTR3C Q8WXA8 1/20 0.71
CYP2D6 P10635 9/20 0.66
USP2 O75604 9/20 0.66
TSHR P16473 8/20 0.62
ALDH1A1 P00352 8/20 0.62
CYP3A4 P08684 7/20 0.62
HSD17B10 Q99714 6/20 0.62
MAPK1 P28482 5/20 0.62
TP53 P04637 5/20 0.62
CYP1A2 P05177 5/20 0.62
CYP2C19 P33261 6/20 0.50
CYP2C9 P11712 5/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30870394 0.83 HTR3A (1.00) HTR3ASIGMAR1HTR3EHTR3BHTR5A
SCHEMBL3138664 0.83 HTR3A (1.00) HTR3ASIGMAR1HTR3EHTR3BHTR5A
SCHEMBL1777946 0.82 HTR1A (0.70) HTR3ASIGMAR1HTR3EHTR3BHTR5A
Hydrochloric Acid SCHEMBL29688470 0.82 HTR3A (0.96) HTR3ASIGMAR1HTR3EHTR3BHTR5A
Hydrochloric Acid SCHEMBL15708159 0.82 HTR3A (0.96) HTR3ASIGMAR1HTR3EHTR3BHTR5A
SCHEMBL1779655 0.76 ADRB1 (0.70) HTR3ASIGMAR1HTR3EHTR3BHTR3D
SCHEMBL1779990 0.74 CYP2D6 (0.55) HTR3ASIGMAR1HTR3EHTR3BHTR3D
SCHEMBL3534699 0.74 HTR3A (0.69) HTR3ASIGMAR1HTR3EHTR3BHTR5A
SCHEMBL29594813 0.74 HTR3A (0.69) HTR3ASIGMAR1HTR3EHTR3BHTR5A
SCHEMBL13131249 0.74 CYP11B1 (0.51) HTR3ASIGMAR1HTR3EHTR3BHTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US claimed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP claimed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US claimed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP claimed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO claimed
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US disclosed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US disclosed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP disclosed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 HTR3A 23/4885SIGMAR1 57/4885HTR3E 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.